Cite
HARVARD Citation
Xu, R. et al. (2021). Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. Lancet gastroenterology and hepatology. pp. 1015-1024. [Online].